TechnoPhage

TechnoPhage S.A. is a clinical-stage biopharmaceutical company operating out of Lisbon, Portugal, that develops biological molecules for several therapeutic areas. Founded in 2005 as a startup within the Institute of Molecular Medicine, the company has grown into an international entity with a focus on infection, neuroscience, and ophthalmology. The firm is led by co-founder and CEO Miguel Garcia, who has a PhD in pharmacy and over two decades of experience in the biotech industry's business development, management, and finance sectors. The leadership team also includes CSO and Deputy CEO Sofia Côrte-Real and Scientific Director Clara Leandro, both of whom hold PhDs in pharmacy and have extensive experience in drug development and biomedical sciences.

The company's business model is centered on advancing a pipeline of proprietary products from early discovery through to clinical development and eventual commercialization. TechnoPhage possesses in-house capabilities for process development and GMP (Good Manufacturing Practice) production, having launched its own manufacturing plant specializing in biologics like bacteriophages and antibody fragments. Revenue generation is anticipated through collaboration agreements and licensing deals with pharmaceutical partners, as well as the future sale of its approved therapeutic products. The company actively collaborates with research centers and universities across Europe, the USA, and Asia to bolster its R&D programs.

TechnoPhage utilizes three core technological platforms: a bacteriophage platform (TP products), a drug repositioning platform (TZ products), and a platform for developing recombinant single-domain antibody fragments (TA products). Its diversified pipeline includes several products in various stages of development. In the area of infection, its leading candidate is TP-102, a bacteriophage cocktail for treating chronic ulcers, such as those associated with diabetic foot infections. TP-102 has received Fast Track Designation and has undergone Phase I/IIa clinical trials. Other infectious disease candidates include TP-122 for respiratory infections and TP-164 for urinary tract infections. In neuroscience, the pipeline features TZ-161 for spinal cord injury, which initiated a Phase 1b/2a clinical trial in July 2025, and TA-191 for an undisclosed indication. The company has also been recognized for its performance and patenting activity in Portugal.

Keywords: biopharmaceutical, bacteriophage therapy, drug development, clinical trials, GMP manufacturing, infection therapeutics, neuroscience, ophthalmology, antibody fragments, drug repositioning, biologics, Lisbon, Miguel Garcia, TP-102, diabetic foot ulcer, spinal cord injury, proprietary technologies, R&D collaboration, pharmaceutical partnerships, biopharma